A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD

References

• Concerta® (methylphenidate hydrochloride extended-release tablets). Full Prescribing Information [package insert]. Titusville (NJ): McNeil Pediatrics; 2008.
   Google Scholar
• Adderall XR® (mixed salts of a single-entity amphetamine product). Full Prescribing Information [package insert]. Lexington (MA): Shire US Inc.; 2017.
   Google Scholar
• Vyvanse® (lisdexamfetamine dimesylate). Full Prescribing Information [package insert]. Lexington (MA): Shire US Inc.; 2017.
   Google Scholar
• Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970–976.
   PubMed Web of Science ®Google Scholar
• McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(6):673–683.
   PubMed Web of Science ®Google Scholar
• Wigal SB, Kollins SH, Childress AC, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.
   PubMedGoogle Scholar
• Wigal SB, Childress AC, Belden HW, et al. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013;23(1):3–10.
   PubMed Web of Science ®Google Scholar
• Mydayis® extended-release capsules (mixed salts of a single-entity amphetamine product). Full Prescribing Information [package insert]. Lexington (MA): Shire US Inc.; 2017.
   Google Scholar
• Weisler RH, Greenbaum M, Arnold V, et al. Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. CNS Drugs. 2017;31(8):685–697.
   PubMed Web of Science ®Google Scholar
• Frick G, Yan B, Adler LA. Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: results of a phase 3, double-blind, randomized, forced-dose trial. J Atten Disord. 2017. Epub ahead of print. DOI:10.1177/1087054717696771
   Web of Science ®Google Scholar
• Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69:1437–1448.
   PubMed Web of Science ®Google Scholar
• Brams M, Childress AC, Greenbaum M, et al. SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: results of a randomized, double-blind placebo-controlled study. J Child Adolesc Psychopharmacol. 2018;28(1):19–28.
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373.
   PubMed Web of Science ®Google Scholar
• Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239–247.
   PubMed Web of Science ®Google Scholar
• Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–639.
   PubMed Web of Science ®Google Scholar
• Wigal T, Childress A, Frick G, et al. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment. Postgrad Med. 2018;130(1):111–121.
   PubMed Web of Science ®Google Scholar
• Wigal T, Brams M, Frick G, et al. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design. Postgrad Med. 2018;130(5):481–493.
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10(1):92–111.
   PubMedGoogle Scholar
• Swanson JM, Lerner M, Wigal T, et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord. 2002;6(Suppl. 1):S73–88.
   PubMedGoogle Scholar
• Dopfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004;13(Suppl. 1):I93–101.
   PubMed Web of Science ®Google Scholar
• Swanson JM, Wigal S, Greenhill LL, et al. Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry. 1998;37(5):519–526.
   PubMed Web of Science ®Google Scholar
• Wigal SB, Greenhill LL, Nordbrock E, et al. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(10):562–569.
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373–374.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-age Children-Present and Lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980–988.
   PubMed Web of Science ®Google Scholar
• Naugle RI, Chelune GJ, Tucker GD. Validity of the Kaufman Brief Intelligence Test. Psychol Assess. 1993;5(2):182.
   Google Scholar
• Conners C. Conners’ Rating Scales-Revised Technical Manual. North Tonawanda (NY): Multi-Health Systems; 2000.
   Google Scholar
• AACAP Work Group on Quality Issues, Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. New York (NY): Guilford Press; 1998.
   Google Scholar
• Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34(1):47–53.
   PubMedGoogle Scholar
• Conners CK, Sitarenios G, Parker JD, et al. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257–268.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
   PubMed Web of Science ®Google Scholar
• Backhaus J, Junghanns K, Broocks A, et al. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res. 2002;53(3):737–740.
   PubMed Web of Science ®Google Scholar
• Tse G, Chan YW, Keung W, et al. Electrophysiological mechanisms of long and short QT syndromes. Int J Cardiol Heart Vasc. 2017;14:8–13.
   PubMed Web of Science ®Google Scholar
• Hysing M, Lundervold AJ, Posserud MB, et al. Association between sleep problems and symptoms of attention deficit hyperactivity disorder in adolescence: results from a large population-based study. Behav Sleep Med. 2015;14:550–564.
   PubMed Web of Science ®Google Scholar
• Tulloch SJ, Zhang Y, McLean A, et al. SLI381(Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22(11):1405–1415.
   PubMed Web of Science ®Google Scholar
• Ermer JC, Shojaei A, Pennick M, et al. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin. 2007;23(5):1067–1075.
   PubMed Web of Science ®Google Scholar
• Adler LA, Frick G, Yan B. A long-term, open-label, safety study of triple-bead mixed amphetamine salts (SHP465) in adults with ADHD. J Atten Disord. 2017. Epub ahead of print. DOI:10.1177/1087054717696770
   Web of Science ®Google Scholar